Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA21 dose-response study in hemodialysis patients with hyperphosphatemia
NCT01521494Phase 2Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Jan 2012
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of iron sucrose in hyperphosphatemia (5 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Change From Baseline in Serum Phosphorus Concentrations at the End of Treatment at 6 weeks. Started Jan 2012; status: completed.
02
Drugs
iron sucrose
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT01521494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01521494.